Publication Name	World Journal of Gastroenterology
Manuscript ID	70046
Country	United States

Received	2021-07-20 21:14
Peer-Review Started	2021-07-20 21:18
To Make the First Decision
Return for Revision	2021-08-06 18:04
Revised	2021-08-10 01:23
Second Decision	2021-11-22 03:33
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-11-25 01:24
Articles in Press	2021-11-25 01:24
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-11-30 23:45
Publish the Manuscript Online	2021-12-03 07:34

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Letter to the Editor
Article Title	Diagnostic biomarkers for pancreatic cancer: An update
Manuscript Source	Invited Manuscript
All Author List	Ming Yang and Chun-Ye Zhang
Funding Agency and Grant Number
Corresponding Author	Ming Yang, DVM, PhD, Postdoctoral Fellow, Department of Surgery, University of Missouri, One Hospital Dr., Medical Science Building, Room M272, Columbia, MO 65212, United States. yangmin@health.missouri.edu
Key Words	Pancreatic ductal adenocarcinoma; Diagnosis; Biomarkers; Panel; Clinical trials
Core Tip	The development of ideal diagnostic biomarkers for pancreatic cancer (PC) is critically important for early diagnosis, large-scale screening, monitoring of therapeutic response, prediction of risk, and prognosis. So far, the only approved serum marker for PC diagnosis is carbohydrate antigen 19-9 (CA 19-9) in the United States; although, many potential biomarkers have been investigated. However, CA 19-9 has low sensitivity; hence, new solutions are needed. Herein, we summarize some of the ongoing clinical trials that aim to investigate the application of biomarkers in PC diagnosis.
Publish Date	2021-12-03 07:34
Citation	Yang M, Zhang CY. Diagnostic biomarkers for pancreatic cancer: An update. World J Gastroenterol 2021; 27(45): 7862-7865
URL	https://www.wjgnet.com/1007-9327/full/v27/i45/7862.htm
DOI	https://dx.doi.org/10.3748/wjg.v27.i45.7862

Full Article (PDF)	WJG-27-7862.pdf
Full Article (Word)	WJG-27-7862.docx
Manuscript File	70046_Auto_Edited.docx
Answering Reviewers	70046-Answering reviewers.pdf
Audio Core Tip	70046-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	70046-Conflict-of-interest statement.pdf
Copyright License Agreement	70046-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	70046-Language certificate.pdf
Peer-review Report	70046-Peer-review(s).pdf
Scientific Misconduct Check	70046-Bing-Fan JR-2.png
Scientific Editor Work List	70046-Scientific editor work list.pdf